Ann: Positive clinical data filed with FDA to support ODD request, page-100

Hang in there sharholders. 90 days from the 14th March, PAA will obtain Orphan Drug Designation and all the perks that go with it. This traditionally doubles the shareprice, particularly one that has recently dropped below bollinger chart levels.

And then the next up uplift is where shares traditionally triple (at least), during an unusually short and combined Phase 2/3 trial.

Add 50% to todays shareprice, then triple that by this time next year and all your frowns will be turned upside down



The statistical significance of what this drug has accomplished is nothing short of lifechanging, actually life saving for 100% of those involved in the trial to date. And the proven odds of that are 1:1000, so people selling because a CEO has stepped down are not looking at the bigger picture. He is not the one in the labcoat, and he only signs off the FDA submissions, all the horsepower is done by the team, remember the drug is the standout, and PAA OWN IT!!

Hold and enjoy the ride, this is a huge year of blockbuster news for PAA!!